Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Enrollment ceased in phase IIb/III trial of Ad5FGF-4

Feb. 4, 2004

Sankyo receives manufacturing approval for Olmetec tablets

Feb. 3, 2004

Aventis scientists design NHE-1 inhibitors for arrhythmia, heart failure, etc.

Feb. 3, 2004

New natural oil stent-coating shows excellent biocompatibility to vascular tissue

Feb. 3, 2004

Antihypertensive effects of tachykinin NK3 receptor antagonists

Feb. 3, 2004

Phase II trials to evaluate VT-111 for ACS

Feb. 2, 2004

Novel Rho kinase inhibitors prepared and tested at Bayer

Feb. 2, 2004

European orphan drug status for sildenafil for PAH

Jan. 30, 2004

Initial proof-of-concept study successfully completed for Provasca

Jan. 30, 2004

GSK scientists develop novel dual ACE/NEP inhibitors

Jan. 29, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
mRNA flu vaccine can activate broad germinal center response
BioWorld
On the eve of the June 17 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, which will discuss Moderna Inc.’s mRNA-1010, researchers...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...